Sort
4,870 grants matching “glp 1”
An oral ROCK2-selective inhibitor for treatment of chronic spinal cord injury
$224,454Kenneth M Rosen · Bioaxone Biosciences, Inc. · R44 · FY2018 · NS
Role of Exercise in the Endocrine Control of Feeding
$224,376University Of Michigan At Ann Arbor · R15 · FY2005 · DK
Development of stapled oxyntomodulin-Fc fusion proteins for the treatment of diabetes and obesity
$224,000Yifang Yang · Transira Therapeutics, Llc · R43 · FY2018 · DK
Treatment of Canine Diabetic Cataracts
$223,906Milton None Wyman · Therapeutic Vision, Inc. · R44 · FY2012 · EY
Surgical Wound Closure Matrices for the Prevention of Superficial Incisional SSI
$223,866Manav Mehta · Gel4med, Inc. · R43 · FY2017 · GM
Small Animal Phenotyping Core
$223,755Barbara A. Gower · University Of Alabama At Birmingham · P30 · FY2009 · DK
Flowable antimicrobial skin scaffolding matrix that promotes regeneration
$223,369Manav Mehta · Gel4med, Inc. · R43 · FY2016 · GM
Phase 2A Study of Exendin for the Treatment of Congenital Hyperinsulinism
$223,231Diva Del Carmen De Leon · Children'S Hosp Of Philadelphia · R01 · FY2015 · FD
Development of a nitric oxide-releasing antiviral gel for the treatment of cervical HPV infections and prevention of downstream malignancies in women
$223,131Carri Geer · Novan, Inc. · R44 · FY2019 · AI
A NOVEL TARGETED DELIVERY SYSTEM FOR CANCER TREATMENT AND DIAGNOSIS
$222,359John Anthony Muraski · Endurx Pharmaceuticals, Inc. · R44 · FY2014 · CA
ASSAY CORE
$222,127Kristin J Bergsland · University Of Chicago · P01 · FY2013 · DK
Early Screening of Breast Lesion Trial (Phase III Pivotal)
$222,084David A. Benaron · Spectros Corporation · R44 · FY2007 · CA
Develop predictive human cardiomyocyte-based all optical assay for cardiotoxicity
$221,686Graham Thomas Dempsey · Q-State Biosciences, Inc. · R43 · FY2015 · HL
Testing Oral Delivery of the Appetite Suppressing Peptide PYY3-36 Through the Vit
$221,352Robert P Doyle · Syracuse University · R15 · FY2013 · DK
A study of hormone-expressing taste cels: in vivo and in vitro
$221,322Josephine Egan · National Institute On Aging · Z01 · FY2008 · AG
Analytical Pharmacology
$221,063Michelle A Rudek · Johns Hopkins University · P30 · FY2021 · CA
Analytical Pharmacology
$221,063Michelle A Rudek · Johns Hopkins University · P30 · FY2019 · CA
Analytical Pharmacology
$221,063Michelle A Rudek · Johns Hopkins University · P30 · FY2020 · CA
Analytical Pharmacology
$221,006Michelle A Rudek · Johns Hopkins University · P30 · FY2018 · CA
Analytical Pharmacology
$220,725Michelle A Rudek · Johns Hopkins University · P30 · FY2017 · CA
GLUCAGON BIOSYNTHESIS AND METABOLISM
$220,611Massachusetts General Hospital · R01 · FY2000 · DK
Development of a novel quinazoline compound for the treatment of spinal muscular
$220,500Christine Didonato · Lurie Children'S Hospital Of Chicago · R21 · FY2010 · NS
Dietary Resistant Starch: The role of PYY and GLP-1 in energy balance
$220,500Roy J Martin · Lsu Pennington Biomedical Research Ctr · R21 · FY2006 · DK
Production of a Nanoparticle Vaccine to Aid in Smoking Cessation
$220,093Sean K Whittier · Hafion, Llc · R43 · FY2020 · DA
Pharmaceutical and Regulatory Core
$219,874David R Friend · Magee-Women'S Res Inst And Foundation · U19 · FY2011 · AI